Published the monthly exercise status for Series 14 stock acquisition rights for October 2026. Number of shares granted: 1,085,300 shares; number of options exercised: 10,853 units; exercise rate: 2.78%; unexercised shares: 390,000 shares (end of previous month) and 379,147 shares (end of month).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4576","jir_company_name":"D. Western Therapeutics Institute, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4576-20261102-01.pdf","jir_short_summary":"Published the monthly exercise status for Series 14 stock acquisition rights for October 2026. Number of shares granted: 1,085,300 shares; number of options exercised: 10,853 units; exercise rate: 2.78%; unexercised shares: 390,000 shares (end of previous month) and 379,147 shares (end of month).","jir_summary":"### Overview\nThis disclosure reports the monthly exercise status of the Series 14 stock acquisition rights (with exercise price adjustment provision). For the subject month, the number of shares granted was 1,085,300 shares, the number of stock acquisition rights actually exercised was 10,853 units, and the newly issued shares after transfer were observed in a distribution of 178 to 1,434 shares. The exercise ratio against the total issued is 2.78%, and unexercised rights stood at 390,000 shares at the end of the previous month and 379,147 shares at the end of the month.\n\n### Impact on Shareholders and Outlook\nGiven the low exercise rate, short-term dilution effects are considered limited. It is necessary to monitor exercise trends and the movement of unexercised rights through future monthly disclosures. For details on past announcement dates, refer to the notice published on September 14, 2026.","jir_financial_highlights":"Number of shares granted: 1,085,300 shares (Unknown)\nNumber exercised relative to total issued: 10,853 units (Unknown)\nExercise rate of stock acquisition rights: 2.78% (Unknown)","jir_category":"","jir_hashtags":"#D.WesternTherapeuticsInstitute, #StockOptions","jir_key_figures":"Number of shares granted: 1,085,300 shares\nNumber of stock acquisition rights exercised: 10,853 units\nNew shares: 178\u20131,434 shares (by applicable date)\nTotal issued: 57,599,412 shares\nNumber of unexercised shares: 390,000 shares (end of previous month) \/ 379,147 shares (end of month)\nExercise ratio: 1.88% (ratio based on exercise restrictions as of end of previous month)","jir_meta_title":"D. Western Therapeutics Institute, Inc. Announces Monthly Exercise Status of Series 14 Stock Acquisition Rights | October 2026","jir_meta_description":"Key points of D. Western Therapeutics Institute, Inc.'s monthly exercise status for Series 14 stock acquisition rights: 1,085,300 shares granted, 10,853 rights exercised, 2.78% exercise rate, unexercised shares decreased from 390,000 to 379,147.","jir_og_title":"D. Western Therapeutics Institute, Inc. Announces Monthly Exercise Status of Series 14 Stock Acquisition Rights | October 2026","jir_og_description":"Report on the monthly exercise status of stock acquisition rights by D. Western Therapeutics Institute, Inc.: 1,085,300 shares granted, 10,853 units exercised, 2.78% exercise rate, unexercised shares declined from the previous month.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59943,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-140086","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n